Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cellmid has entered into an agreement with Antitope for the humanization of its lead therapeutic monoclonal antibody candidate.
Subscribe to our email newsletter
The collaboration is expected to deliver a drug candidate, a first in class humanised anti-midkine antibody, using Cellmid’s patented sequence and Antitope’s proprietary EpiScreen and Composite Human Antibody technologies.
Under the agreement, Antitope is expected to generate sufficient humanized antibody for preclinical testing using their proprietary CHO expression system.
Cellmid CEO Maria Halasz said they have conducted a global search to find the right humanisation partner for the anti-midkine assets.
Antitope chief scientific officer and co-founder Matthew Baker said they are excited about the prospects for Cellmid’s therapeutic antibody against midkine and believe the development of fully humanized, non-immunogenic Composite Human Antibodies will support the development of safe and effective therapies.